Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CEOP-IMVP-DEXA IN THE TREATMENT OF AGGRESSIVE LYMPHOMAS - AN AUSTRIANMULTICENTER TRIAL
Autore:
FRIDRIK MA; HAUSMANINGER H; LINKESCH W; STOGER M; SILL H; NEUBAUER M; SEEWANN HL; KLOCKER J; HAIDINGER R; SCHILLER L; PONT J; RAUDASCHL G; FOLK M; RADASZKIEWICZ T;
Indirizzi:
AOKH LINZ,DEPT MED 1,KRANKENHAUSSTR 9 A-4020 LINZ AUSTRIA
Titolo Testata:
Journal of clinical oncology
fascicolo: 1, volume: 14, anno: 1996,
pagine: 227 - 232
SICI:
0732-183X(1996)14:1<227:CITTOA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; COMBINATION CHEMOTHERAPY; INTENSIVE CHEMOTHERAPY; REGIMEN; ADRIAMYCIN; DISEASE; CHOP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Fridrik et al., "CEOP-IMVP-DEXA IN THE TREATMENT OF AGGRESSIVE LYMPHOMAS - AN AUSTRIANMULTICENTER TRIAL", Journal of clinical oncology, 14(1), 1996, pp. 227-232

Abstract

Purpose: This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter setting of university and community hospitals. Patients and Methods: We tested a hybrid protocol of two non-cross-resistant regimens, cyclophosphamide, epirubicin, vincristine, and prednisolone (CEOP) and ifosfamide, etoposide (VP-16), methotrexate, and dexamethasone (IMVP-Dexa) given every fourth week, three to six times according to response, in patients with untreated intermediate and high-grade non-Hodgkin's lymphoma. TenAustrian centers entered 81 patients onto this multicenter trial. Eleven patients were excluded. The median age was 55 years. Twenty-six of70 patients had stage III or IV disease. The distribution among international risk categories low, intermediate-low, intermediate-high, andhigh was 20%, 34%, 23%, and 23%, respectively. Results: Of 70 eligible patients, 56 (80%) had a complete remission and seven (10%) a partial remission. After a median observation time of 36 months, the estimated time to relapse and overall survival rates are 67% and 72%, respectively. Age and Karnofsky index were the only independent risk factors for survival. Toxicity was primarily hematologic, with a median granulocyte nadir of 0.56 x 10(9)/L. Sixty-seven percent of patients had infections; 25.7% were severe World Health Organization (WHO) grade III or IV. There were three treatment-related deaths. Conclusion: CEOP-IMVP-Dexa chemotherapy is safe and feasible on a groupwide basis even whenused in community hospitals. Neutropenic infections are the major complications. A 72% 3-year survival rate in patients with intermediate- and high-grade non-Hodgkin's lymphoma warrants further studies. These data are the basis for a randomized trial to compare cyclophosphamide,doxorubicin, vincristine, and prednisolone (CHOP) with CEOP/IMVP-Dexa. (C) 1996 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 13:51:15